Malaria is an illness caused by tiny parasites that are spread through mosquito bites and can lead to fever, chills, and flu‑like symptoms. The study drug MK-7602 is given as a hard capsule taken by mouth, and a matching placebo capsule that contains no active medicine is also used for comparison.

The main goal of the trial is to see whether multiple daily doses of the medication are safe and well tolerated in healthy volunteers and to gather early information on its pharmacokinetics, which means how the body absorbs, distributes, and removes the drug. Researchers will watch for any adverse event (side effect) and will measure the amount of drug in the blood, referred to as plasma, at several time points to understand how long the drug stays in the system, its half‑life, and how quickly it is cleared.

Participants will take the assigned capsule once each day for seven days. During this period, short clinic visits will be scheduled to collect blood samples and check for any side effects. After the final dose, additional blood draws will be done to complete the safety checks and the drug‑level measurements, after which participants will be monitored for a short follow‑up period.